非小细胞肺癌分子靶向治疗研究进展
Research Progress of Molecular Target Therapy in Non-Small Cell Lung Cancer

作者: 张 琨 :上海中医药大学,上海; 寿伟臻 :上海中医药大学附属龙华医院,上海;

关键词: 非小细胞肺癌靶向治疗研究进展Non-Small Cell Lung Cancer Targeted Therapy Research Progress

摘要:
肺癌是一种发病率、病死率均较高的恶性肿瘤,临床上多采用手术、放疗、化疗等治疗手段,但是不得不承认的是,除了对于早期肺癌及体质较好的患者有较为可观的疗效外,其治疗效果的上升空间相对局限。肺癌分子靶向治疗与传统的手术、放疗、化疗相比,因其与肿瘤细胞上特有的靶点产生特异性结合,精确打击肿瘤细胞而又不伤害正常的细胞,从而具有毒副反应较小的优点,这种新的治疗方式提高了患者的生活质量。本文对肺癌生物靶向治疗药物的研究进展进行综述。

Abstract: Lung cancer is a malignant tumor with high incidence rate and mortality rate. Clinically, treatment means, like surgery, radiotherapy, chemotherapy treatment, etc. are used. However, it had to admit that, besides the considerable effect for patients with early lung cancer and patients with good physique, the rising space of the treatment effect relatively limited. Lung cancer molecular target-ing therapy, compared with traditional surgery, radiotherapy and chemotherapy, due to its specific binding to the specific target of tumor cells, precisely attacking tumor cells without harm to the normal cells, has got the advantage of less toxic side effect. This new treatment modality improves patients’ life quality. This paper reviewed the research progress of drug treatment to lung cancer biological target.

文章引用: 张 琨 , 寿伟臻 (2016) 非小细胞肺癌分子靶向治疗研究进展。 临床医学进展, 6, 17-22. doi: 10.12677/ACM.2016.61004

参考文献

[1] Pakkala, S. and Ramalingam, S.S. (2009) Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling in Non Small Cell Lung Cancer Therapy. Clinical Lung Cancer, 10, S17-S23.
http://dx.doi.org/10.3816/CLC.2009.s.003

[2] 西安知先信息技术有限公司. 肺癌的靶向治疗时代已来临[J]. 第三军医大学学报, 2014(3): 193.

[3] 周严, 韩宝惠. 靶向治疗时代下的非小细胞肺癌化疗现状与进展[J]. 上海医药, 2015(15): 9-13.

[4] 赵颖, 王芮, 付桂英. 非小细胞肺癌分子靶向治疗药物的研究进展[J]. 实用临床医药杂志, 2014, 18(1): 140-142.

[5] Fukuoka, M., Yano, S., Giaccone, G., et al. (2003) Multi-Instiutional Randomized Phase II Trail of Gefitinib for Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 21, 2237-2246.
http://dx.doi.org/10.1200/JCO.2003.10.038

[6] Mollberg, N., Surati, M., Demchuk, C., et al. (2011) Mind-Mapping for Lung Cancer: Toward a Personalized Therapeutics Approach. Advances in Therapy, 28, 173-194.
http://dx.doi.org/10.1007/s12325-010-0103-9

[7] 倪子俞. 谈肺癌的靶向治疗[J]. 临床肺科杂志, 2010, 15(4): 451-452.

[8] 满韦韬, 黄泳. 晚期非小细胞肺癌的靶向治疗研究进展[J]. 中国癌症杂志, 2010, 20(4): 308-311.

[9] 蔡智慧, 张翠英. 肺癌的分子靶向治疗进展[J]. 西部医学, 2014, 26(1): 122-123.

[10] Johnson, D.H., Fehrenbiicher, L., Novotny, W.F., et al. (2004) Randomized Phase II Trial Comparing Bevacizumab plus Car-boplatin and Paclitaxel with Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Journal of Clinical Oncology, 22, 2184-2191.
http://dx.doi.org/10.1200/JCO.2004.11.022

[11] Reck, M., Von Pawel, J., Zatloukal, P., et al. (2009) Phase III Trial of Cisplatin plus Gemcitabine with Either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer: AVAiI. Journal of Clinical Oncology, 27, 1227-1234.
http://dx.doi.org/10.1200/JCO.2007.14.5466

[12] Heist, R.S., Fidias, P., Huberman, M., et al. (2008) A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 3, 1153-1158.
http://dx.doi.org/10.1097/JTO.0b013e318187273f

[13] 王艇, 罗黎力. 贝伐单抗治疗晚期非小细胞肺癌的系统评价[J]. 中国实用医药, 2008, 3(5): 1-2.

[14] 薛聃, 周彦斌. 非小细胞肺癌分子靶向药物的研究进展[J]. 国际内科学杂志, 2008, 35(7): 419-422.

[15] 耿丽, 王瑞. 恩度联合培美曲塞方案二线治疗晚期非小细胞肺癌临床观察[J]. 医药论坛杂志, 2011, 32(12): 63- 65.

[16] 郑青平, 倪秉强, 伍美娟, 罗平, 罗展雄, 张志红, 徐艺安. 肝癌放疗前后血浆VEGF表达的临床意义[J]. 重庆医学, 2010, 39(3): 288-289.

[17] 王洋, 梁岳培. 抗VEGF和抗EGFR靶向治疗非小细胞肺癌的研究进展[J]. 临床医学工程, 2011, 18(2): 312-313.

[18] Hirsch, F.R., Varella-Garcia, M., Bunn Jr., P.A., et al. (2003) Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation between Gene Copy Number and Protein Expression and Impact on Prognosis. Journal of Clinical Oncology, 21, 3798-3807.
http://dx.doi.org/10.1200/JCO.2003.11.069

[19] 刘赞, 郭丽丽, 唐俊舫, 等. 吉非替尼治疗晚期非小细胞肺癌临床疗效分析[J]. 中国临床医生, 2011, 39(7): 29- 31.

[20] Kris, M.G., Natale, R.B., Herbst, R.S., et al. (2003) Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer Randomized Trail. JAMA, 290, 2149-2158.
http://dx.doi.org/10.1001/jama.290.16.2149

[21] Fukuoka, M., Yano, S., Giaccone, G., et al. (2003) Mul-ti-Institutional Randomized Phase II Trail of Gefitinib for Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 21, 2237-2246.
http://dx.doi.org/10.1200/JCO.2003.10.038

[22] Sequist, L.V., Martins, R.G., Spigel, D., et al. (2008) First-Line Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring Somatic EGFR Mutations. Journal of Clinical Oncology, 26, 2442-2449.
http://dx.doi.org/10.1200/JCO.2007.14.8494

[23] Zhu, J.Q., Zhong, W.Z., Zhang, G.C., et al. (2008) Better Sur-vival with EGFR Exon 19 than Exon 2 Mutations in Gefltinlb-Treated Non-Small Cell Lung Cancer Patients Is Due to Differential Inhibition of Downstream Signals. Cancer Letters, 265, 307-317.
http://dx.doi.org/10.1016/j.canlet.2008.02.064

[24] Akeriey, W., Boucher, K.M., Bentz, J.S., et al. (2009) A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage B-IV Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 4, 214-219.
http://dx.doi.org/10.1097/JTO.0b013e3181943bb9

[25] Costa, D.B., Nguyen, K.S., Cho, B.C., et al. (2008) Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinb. Clinical Cancer Research, 14, 7060-7067.
http://dx.doi.org/10.1158/1078-0432.CCR-08-1455

[26] 彭培建, 林忠, 张红雨, 等. 厄洛替尼治疗晚期非小细胞肺癌患者的疗效及安全性研究[J]. 中国全科医学, 2010, 13(13): 1420-1423.

[27] 陈志城. 厄洛替尼及其有关热点问题[J]. 中国处方药, 2005(4): 70-72.

[28] Herbst, R.S., Prager, D., Hermann, R., et al. (2005) TRIBUTE: A Phase Ⅲ Trial of Erlotinib Hydrochloride (OSI2774) Combined with Carbop Latin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 23, 5892-5899.
http://dx.doi.org/10.1200/JCO.2005.02.840

[29] 汪琪琪, 郭文浩, 王晓华, 等. 西妥昔单抗治疗晚期肥效细胞肺癌的研究进展[J]. 华西医学, 2006, 21(3): 663- 664.

[30] Belani, C.P., Schreeder, M.T., Steis, R.G., et al. (2008) Cetuximab in Combination with Carboplatin and Docetaxel for Patients with Metastatic or Advanced-Stage Non-Small Cell Lung Cancer: A Multicenter Phase 2 Study. Cancer, 113, 2512-2517.
http://dx.doi.org/10.1002/cncr.23902

[31] Pirker, R. (2008) Cetuximab: Potential Role as First Line Treatment for Advanced Non-Small Cell Lung Cancer. Clinical Advances in Hematology & Oncology, 6, 735-736.

[32] 黄晓慧. 非小细胞肺癌的多靶点联合靶向治疗进展[J]. 现代中西医结合杂志, 2013, 22(12): 1363-1365.

[33] Stewart, D.J. (2008) Design of Phase II Cancer Trials Using a Continuous End Point of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 100, 445-446.
http://dx.doi.org/10.1093/jnci/djn021

[34] Ping, G., Wang, H.-M., Wang, W.-M., et al. (2011) Stmitinib in Pretreated Advanced Non-Small-Cell Lung Carcinoma: A Primary Result from Asian Population. Medical Oncology, 28, 578-583.
http://dx.doi.org/10.1007/s12032-010-9500-9

[35] 周爱萍. 多靶点抗肿瘤药物舒尼替尼研究进展[J]. 药物与临床, 2009, 7(1): 48-52.

[36] Socinski, M.A., Novello, S., Brahmer, J.R., et al. (2008) Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small Cell Lung Cancer. Journal of Clinical Oncology, 26, 650-656.
http://dx.doi.org/10.1200/JCO.2007.13.9303

[37] Nlovello, S., Scagliotti, G.V., Rosell, R., et al. (2009) Phase II Study of Continuous Daily Sunitinib Dosing in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Journal of Cancer, 101, 1543-1548.
http://dx.doi.org/10.1038/sj.bjc.6605346

[38] Morabito, A., Piccirillo, M.C., Falasconi, F., et al. (2009) Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions. Oncologist, 14, 378-390.
http://dx.doi.org/10.1634/theoncologist.2008-0261

[39] 李梦君, 涂超, 贺洁宇, 等. 凡德他尼治疗晚期非小细胞肺癌的Meta分析[J]. 肿瘤药学, 2012, 2(5): 385-391.

[40] Nlatale, R.B., Bodkin, D., Govindan, R., et al. (2009) Vandetanib versus Gefitinib in Patients with Advanced Non- Small Cell Lung Cancer Results from a Two-Part, Double-Blind, Randomized Phase II Study. Journal of Clinical Oncology, 27, 2523-2529.
http://dx.doi.org/10.1200/JCO.2008.18.6015

分享
Top